Next Article in Journal
Lithium and Erectile Dysfunction: An Overview
Next Article in Special Issue
Bioengineered Cystinotic Kidney Tubules Recapitulate a Nephropathic Phenotype
Previous Article in Journal
LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights
Previous Article in Special Issue
In Vitro and In Vivo Models to Study Nephropathic Cystinosis
 
 
Review
Peer-Review Record

Muscle and Bone Impairment in Infantile Nephropathic Cystinosis: New Concepts

by Dieter Haffner 1,2,*, Maren Leifheit-Nestler 1,2, Candide Alioli 3 and Justine Bacchetta 3,4
Reviewer 1: Anonymous
Reviewer 2:
Submission received: 11 November 2021 / Revised: 28 December 2021 / Accepted: 1 January 2022 / Published: 5 January 2022
(This article belongs to the Special Issue Cellular and Molecular Mechanisms of Nephropathic Cystinosis)

Round 1

Reviewer 1 Report

The authors present a detailed review of the current literature in relation to new concepts in muscle and bone impairment in infantile nephropathic cystinosis. The manuscript is of sufficient quality to be suitable for publication with the following minor revisions:

  • Authors should include some discussion on the potential of the novel stem cell therapy in treatment of muscle and bone impairment in cystinotic patients.
  • The review, while similar to a recent review (Machuca-Gayet et al 2021, IJMS), is sufficiently different to warrant publication. However inclusion of some discussion of the potential role of mitochondrial dysfunction should be considered.

Author Response

Authors should include some discussion on the potential of the novel stem cell therapy in treatment of muscle and bone impairment in cystinotic patients.

Reply: Thank you for this suggestion which we incorporated in the revised manuscript line 1412-14. 

 

The review, while similar to a recent review (Machuca-Gayet et al 2021, IJMS), is sufficiently different to warrant publication. However inclusion of some discussion of the potential role of mitochondrial dysfunction should be considered.

Reply: Thank you for this suggestion which we incorporated in the revised manuscript line 952-956 . 

Author Response File: Author Response.pdf

Reviewer 2 Report

In this MS the authors have made a review of muscle and bone disease in nephropatic cysrinosis, a condition in which  CKD patients have mineral abnormalities that are distinct from those in CKD stemming from other causes.The review is detailed and easy to follow. I have a few concerns, which are released to the authors as follows:

 

Major

 

-.. eventually copper deficiency which all contribute to impaired bone growth (25,26). the role of acidemia in impairing growth seems to be overlooked.

 

-Please clarify these two contradictory sentences:..line 165  increased expression in the number of sclerostin and FGF23-expressing osteocytes, causing progressive elevations in the plasma concentrations of these bone-derived factors

 

and, line 80:

introduction: .. However, there was a tendency towards low parathyroid hormone (PTH) and low fibroblast growth factor 23 (FGF23) levels..

 

-line 243-278. This is a very long description that could be usefully shortened.

 

-Line 315-319 Please consider that studies on vitamin D supplementation were essentially negative on muscle (Front Nutr. 2021 Aug 12;8:701386).

 

-line 250.. This extends the concept coming from studies in adult CKD patients that elevated  circulating FGF23 and sclerostin are the earliest detectable changes of CKD-MBD to the  pediatric CKD population.please add a reference

 

-Targeting IL1β pathway may improve muscle wasting..please consider that also IL6, which inot specific of the inflammasome seems to be a therapeutic target in CKD.

 

-the manuscripts needs english editing (assesment, 25 OH vitamin D, cysteramine,vitamin d, deformaties etc..)

Minor

Figure permissions need to be enclosed

Author Response

-.. eventually copper deficiency which all contribute to impaired bone growth (25,26). the role of acidemia in impairing growth seems to be overlooked.

Reply: This important topic was incorporated in the revised manuscript on line 180-181.

-Please clarify these two contradictory sentences:..line 165  increased expression in the number of sclerostin and FGF23-expressing osteocytes, causing progressive elevations in the plasma concentrations of these bone-derived factors

and, line 80:

introduction: .. However, there was a tendency towards low parathyroid hormone (PTH) and low fibroblast growth factor 23 (FGF23) levels..

Reply: Sorry for this misleading sentences. We now make clear in the revised manuscript that in CKD patients suffering from other causes than cystinosis the first sign of bone disease is an increased secretion of FGF23 and sclerostin in bone, whereas this is not the case in cystinosis. 

-line 243-278. This is a very long description that could be usefully shortened.

Reply: This section was substantially shortened.

-Line 315-319 Please consider that studies on vitamin D supplementation were essentially negative on muscle (Front Nutr. 2021 Aug 12;8:701386).

Reply: This was edited accordingly.

-line 250.. This extends the concept coming from studies in adult CKD patients that elevated  circulating FGF23 and sclerostin are the earliest detectable changes of CKD-MBD to the  pediatric CKD population.please add a reference

Reply: This sentence was deleted in order to shorten this section.

-Targeting IL1β pathway may improve muscle wasting..please consider that also IL6, which inot specific of the inflammasome seems to be a therapeutic target in CKD.

Reply: This was edited accordingly.

-the manuscripts needs english editing (assesment, 25 OH vitamin D, cysteramine,vitamin d, deformaties etc..)

Reply: The manuscript was edited by a native english speaker (Angela Bain Emslie) and all changes are given in the tracking mode.

Minor

Figure permissions need to be enclosed

Reply: Last time this was not possible for me to upload this, just could not find the right button,. hope that this will be possible now. 

Round 2

Reviewer 2 Report

Thank you for nice review

Back to TopTop